Related Experiment Video
Updated: Jul 10, 2026
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
Transcriptional profiling of non-small cell lung cancer cells with activating EGFR somatic mutations
Kuicheon Choi1, Chad J Creighton, David Stivers
1Department of Thoracic/Head and Neck Medical Oncology, M. D. Anderson Cancer Center, The University of Texas, Houston, Texas, United States of America.
Background:
Activating somatic mutations in epidermal growth factor receptor (EGFR) confer unique biologic features to non-small cell lung cancer (NSCLC) cells, but the transcriptional mediators of EGFR in this subgroup of NSCLC have not been fully elucidated.
Methodology/Principal Findings:
Here we used genetic and pharmacologic approaches to elucidate the transcriptomes of NSCLC cell lines. We transcriptionally profiled a panel of EGFR-mutant and -wild-type NSCLC cell lines cultured in the presence or absence of an EGFR tyrosine kinase inhibitor. Hierarchical analysis revealed that the cell lines segregated on the basis of EGFR mutational status (mutant versus wild-type), and expression signatures were identified by supervised analysis that distinguished the cell lines based on mutational status (wild-type versus mutant) and type of mutation (L858R versus Delta746-750). Using an EGFR mutation-specific expression signature as a probe, we mined the gene expression profiles of two independent cohorts of NSCLC patients and found the signature in a subset. EGFR tyrosine kinase inhibitor treatment regulated the expression of multiple genes, and pharmacologic inhibition of the protein products of two of them (PTGS2 and EphA2) inhibited anchorage-independent growth in EGFR-mutant NSCLC cells.
Conclusions/Significance:
We have elucidated genes not previously associated with EGFR-mutant NSCLC, two of which enhanced the clonogenicity of these cells, distinguishing these mediators from others previously shown to maintain cell survival. These findings have potential clinical relevance given the availability of pharmacologic tools to inhibit the protein products of these genes.
Insights
Researchers identified new genes involved in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Inhibiting two of these genes, PTGS2 and EphA2, reduced tumor cell growth, offering potential new therapeutic targets for NSCLC patients.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Activating somatic mutations in the epidermal growth factor receptor (EGFR) are key drivers in a subset of non-small cell lung cancer (NSCLC).
- The specific transcriptional mediators influenced by EGFR mutations in NSCLC remain incompletely understood.
- Understanding these mediators is crucial for developing targeted therapies.
Purpose of the Study:
- To elucidate the transcriptomes of NSCLC cell lines with different EGFR mutational statuses.
- To identify novel transcriptional mediators associated with EGFR-mutant NSCLC.
- To investigate the functional role of identified mediators in cancer cell growth.
Main Methods:
- Transcriptional profiling of EGFR-mutant and wild-type NSCLC cell lines.
- Analysis of gene expression signatures based on EGFR mutational status and specific mutation types (L858R vs. Delta746-750).
- Mining patient cohorts using EGFR mutation-specific expression signatures.
- Pharmacologic inhibition of identified gene products (PTGS2 and EphA2) in EGFR-mutant NSCLC cells.
Main Results:
- NSCLC cell lines segregated based on EGFR mutational status.
- Distinct expression signatures identified for wild-type versus mutant EGFR NSCLC, and between L858R and Delta746-750 mutations.
- EGFR tyrosine kinase inhibitor treatment modulated the expression of multiple genes.
- Inhibition of PTGS2 and EphA2 significantly impaired anchorage-independent growth of EGFR-mutant NSCLC cells.
Conclusions:
- New genes, not previously linked to EGFR-mutant NSCLC, were identified.
- Two identified genes (PTGS2 and EphA2) enhance cancer cell clonogenicity.
- These findings suggest potential therapeutic strategies targeting PTGS2 and EphA2 in EGFR-mutant NSCLC.
